Saad Dina E, Mansour Somaya Z, Kandil Eman I, Hassan Asmaa, Moawed Fatma S M, Elbakry Mustafa M M
Radiation Biology Research, National Center for Radiation Research and Technology, Egyptian Atomic Energy Authority, Cairo, Egypt.
Biochemistry Department, Faculty of Science, Ain-Shams University, Cairo, Egypt.
BMC Pharmacol Toxicol. 2025 Jan 13;26(1):6. doi: 10.1186/s40360-024-00831-w.
Hepatic encephalopathy (HE) is a syndrome that arises from acute or chronic liver failure. This study was devised to assess the impact of a combination of boswellic acid (BA) and low doses of gamma radiation (LDR) on thioacetamide (TAA)-induced HE in an animal model. The effect of daily BA treatment (175 mg/kg body weight, for four weeks) and/or fractionated low-dose γ-radiation (LDR; 0.25 Gy, twice the total dose of 0.5 Gy) was evaluated against TAA (200 mg/kg, intraperitoneal) twice-weekly for four weeks to induce liver damage and HE in rats. TAA-exposed rats exhibited a significant elevation in serum activities of liver enzymes (GGT, ALP) and plasma ammonia levels at P < 0.05 (Duncan's test) compared to the control group. Moreover, there was an increase in the levels of proinflammatory cytokines (IL6, IL12, IL18) in the TAA-exposed animals accompanied by a depletion in the activities of paraoxonase-1 and neurotransmitter contents compared with normal control rats (P < 0.05). However, the administration of BA alone or in combination with LDR led to improvements in liver and brain parameter indices. Furthermore, the histopathological assessments of liver and brain tissues supported the findings of the biochemical investigations. From the statistical analysis, it can be concluded that the combined administration of BA and exposure to LDR may possess potential hepatoprotective effects against hepatic encephalopathy-associated hyperammonemia and the consequent damage to the liver and brain. This study proposes that a combination of therapeutic approaches, LDR and BA could be a new therapeutic candidate for the management of hepatic encephalopathy.
肝性脑病(HE)是一种由急性或慢性肝功能衰竭引起的综合征。本研究旨在评估乳香酸(BA)和低剂量γ辐射(LDR)联合使用对硫代乙酰胺(TAA)诱导的动物模型肝性脑病的影响。评估了每日BA治疗(175mg/kg体重,持续四周)和/或分次低剂量γ辐射(LDR;0.25Gy,总剂量0.5Gy,分两次)对大鼠的影响,每周两次腹腔注射TAA(200mg/kg),持续四周,以诱导肝损伤和肝性脑病。与对照组相比,TAA处理的大鼠血清肝酶(GGT、ALP)活性和血浆氨水平在P<0.05(邓肯检验)时有显著升高。此外,与正常对照大鼠相比,TAA处理的动物促炎细胞因子(IL6、IL12、IL18)水平升高,同时对氧磷酶-1活性和神经递质含量降低(P<0.05)。然而,单独给予BA或与LDR联合使用可改善肝脏和脑参数指标。此外,肝脏和脑组织的组织病理学评估支持了生化研究的结果。从统计分析可以得出结论,BA联合LDR暴露可能对肝性脑病相关的高氨血症以及随后的肝脏和脑损伤具有潜在的肝保护作用。本研究提出,LDR和BA这两种治疗方法的组合可能是治疗肝性脑病的一种新的治疗选择。